Recent evidence indicates a median duration of 9 days IV with change to highly bioavailable oral agent(s) to complete 6 weeks was not shown to be noninferior to 12 weeks total duration [Bernard, NEJM 2021]. Recommend consult Infectious Diseases.  OVIVA trial showed non-inferiority of early (within 7 days after surgery or start of antibiotic treatment) oral therapy compared with IV therapy with shorter duration of hospital stay and lower risk of IV complications [NEJM 2019;380:425-36].  Oral options, if susceptible, include:  amoxicillin, clindamycin (associated with higher recurrence rate [Antibiotics 2021;10:475-88]), linezolid.